Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325162 · ClinicalTrials.gov registry record · NA
Development of Optical Biometer
A NA study of Cataract and IOL Surgery, sponsored by Cassini Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07325162: Recruiting NA study of Cataract and IOL Surgery, sponsored by Cassini Technologies.
NCT07325162 is a NA study of Cataract and IOL Surgery that is actively recruiting participants, run by Cassini Technologies. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07325162, a NA study of Cataract and IOL Surgery, is actively recruiting participants, sponsored by Cassini Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The Helioscope (Cassini Technologies B.V.) is a novel device under development that aims at combining LED-based corneal topography and SS-OCT to provide accurate and fast measurements of both the corneal shape and the ocular biometry. To that end, the hardware and software of the Cassini color-LED topographer (Cassini Technologies B.V.) is combined with a novel SS-OCT device. While the new Helioscope can largely be evaluated using data acquired with healthy eyes, one of its main use-cases is providing input for IOL power formulae for cataract surgery. Thus, it is essential that the device can perform measurements in eyes with (dense) cataract. As cataract changes the optical properties of the crystalline lens and the OCT measurement is optical, this is not a given. This study therefore seeks a dataset of Helioscope measurements performed in eyes with cataract that can be used to develop the software algorithms of the Helioscope.
Primary Outcome
Primary endpoint: Biometric ocular parameters of axial length, anterior chamber depth, central corneal thickness, keratometry, lens thickness and limbal white to white will be measured by the Helioscope device in 200 eyes.
Conditions Studied
Interventions
- DEVICE New Investigational Optical Biometer (Device)
- DEVICE Comparator Device A (Cassini Ambient)
- DEVICE omparator Device B (Argos)
Study Locations (1)
South Carolina
- Bishop Eye Center - Hilton Head Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2026-03-30 |
| Phase | NA |
What NCT07325162 shows while recruiting
NCT07325162 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cataract and IOL Surgery appearing as the primary indexed condition, and to 3 interventions - of which New Investigational Optical Biometer (Device) is the first listed.
NCT07325162 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT07325162 about?
NCT07325162 is a clinical study titled "Development of Optical Biometer". The Helioscope (Cassini Technologies B.V.) is a novel device under development that aims at combining LED-based corneal topography and SS-OCT to provide accurate and fast measurements of both the corneal shape and the ocular biometry. To that end, the hardware and software of the Cassini color-LED t...
What is the current status of trial NCT07325162?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-11-07. Estimated completion is 2026-03-30.
What conditions does trial NCT07325162 study?
This clinical trial studies the following conditions: Cataract and IOL Surgery.
What interventions are being tested in trial NCT07325162?
The interventions under investigation include: New Investigational Optical Biometer (Device) (DEVICE), Comparator Device A (Cassini Ambient) (DEVICE), omparator Device B (Argos) (DEVICE).
Who is sponsoring clinical trial NCT07325162?
This trial is sponsored by Cassini Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325162 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract and IOL Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07325162's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI